Novel Immunotherapy Combos Target TIM-3 and PD-1/PD-L1 Networks
OncLive,
The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung…
The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung…
NATIONAL HARBOR, MD. – The combination of bempegaldesleukin and nivolumab produced durable responses in a phase 1/2 trial of…